CA1314219C - Use of exogenous gangliosides in tumoral diseases as a protective factor against toxicity by antitumoral drugs - Google Patents

Use of exogenous gangliosides in tumoral diseases as a protective factor against toxicity by antitumoral drugs

Info

Publication number
CA1314219C
CA1314219C CA000540885A CA540885A CA1314219C CA 1314219 C CA1314219 C CA 1314219C CA 000540885 A CA000540885 A CA 000540885A CA 540885 A CA540885 A CA 540885A CA 1314219 C CA1314219 C CA 1314219C
Authority
CA
Canada
Prior art keywords
gangliosides
composition according
vincristine
mixture
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA000540885A
Other languages
English (en)
French (fr)
Inventor
Francesco Della Valle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fidia SpA
Original Assignee
Fidia SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia SpA filed Critical Fidia SpA
Application granted granted Critical
Publication of CA1314219C publication Critical patent/CA1314219C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA000540885A 1986-06-30 1987-06-29 Use of exogenous gangliosides in tumoral diseases as a protective factor against toxicity by antitumoral drugs Expired - Fee Related CA1314219C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT8648203A IT1208751B (it) 1986-06-30 1986-06-30 Possibile uso dei gangliosidi esogeni in malattie tumorali come fattore protettivo contro la neurotossicita' da farmaci antitumorali
IT48203A/86 1986-06-30

Publications (1)

Publication Number Publication Date
CA1314219C true CA1314219C (en) 1993-03-09

Family

ID=11265194

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000540885A Expired - Fee Related CA1314219C (en) 1986-06-30 1987-06-29 Use of exogenous gangliosides in tumoral diseases as a protective factor against toxicity by antitumoral drugs

Country Status (16)

Country Link
US (1) US5229373A (OSRAM)
EP (1) EP0251298B1 (OSRAM)
JP (1) JPS6327434A (OSRAM)
AT (1) ATE69381T1 (OSRAM)
AU (1) AU601988B2 (OSRAM)
BE (1) BE1000723A4 (OSRAM)
CA (1) CA1314219C (OSRAM)
DE (2) DE3721562A1 (OSRAM)
DK (1) DK165621C (OSRAM)
ES (1) ES2038621T3 (OSRAM)
FR (1) FR2601248B1 (OSRAM)
GR (2) GR871005B (OSRAM)
IL (1) IL82944A (OSRAM)
IT (1) IT1208751B (OSRAM)
LU (1) LU86930A1 (OSRAM)
ZA (1) ZA874597B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1254280B (it) * 1992-03-13 1995-09-14 Fidia Spa Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson
US6765087B1 (en) * 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DE4430041A1 (de) † 1994-08-24 1996-02-29 Milupa Ag Allergieprotektive Formelnahrung
US5567684A (en) * 1994-09-14 1996-10-22 The Regents Of The University Of California Synthetic ganglioside derivatives
NZ531139A (en) 2001-08-29 2007-09-28 Neose Technologies Inc Synthetic ganglioside derivatives and compositions thereof
WO2004080960A2 (en) 2003-03-06 2004-09-23 Neose Technologies Inc. Methods and compositions for the enzymatic synthesis of gangliosides
EP2282723A2 (en) * 2008-03-26 2011-02-16 University of Oxford Endoplasmic reticulum targeting liposomes
EP3175857A1 (en) 2009-03-25 2017-06-07 Seneb Biosciences Inc. Glycolipids as treatment for disease
US20120148547A1 (en) * 2009-09-01 2012-06-14 Hadasit Medical Reasearch Services & Development Ltd. Combination of vitamin e and beta-glycosphingolipids in compositions and methods for preventing and treating hepatic disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1168205B (it) * 1983-07-21 1987-05-20 Wellcome Italia Derivato di monsialo ganglioside dotato di attivita' antibatterica, antifungina ed antitumorale, composizioni che lo contengono e procedimento per la loro preparazione
IT1182209B (it) * 1985-02-18 1987-09-30 Fidia Farmaceutici Uso terapeutico del monosialoganglioside gm1 e dei suoi derivati in gravi patologie di infarti cerebrali

Also Published As

Publication number Publication date
DK333787A (da) 1987-12-31
DE3774501D1 (de) 1991-12-19
ATE69381T1 (de) 1991-11-15
DK165621B (da) 1992-12-28
GR3003790T3 (OSRAM) 1993-03-16
DE3721562A1 (de) 1988-03-03
IL82944A (en) 1993-04-04
ES2038621T3 (es) 1993-08-01
US5229373A (en) 1993-07-20
EP0251298B1 (en) 1991-11-13
AU7490887A (en) 1988-01-07
ZA874597B (en) 1988-03-30
JPS6327434A (ja) 1988-02-05
GR871005B (en) 1987-10-23
AU601988B2 (en) 1990-09-27
DK333787D0 (da) 1987-06-29
FR2601248B1 (fr) 1989-08-25
DK165621C (da) 1993-06-01
BE1000723A4 (fr) 1989-03-21
IT1208751B (it) 1989-07-10
EP0251298A2 (en) 1988-01-07
LU86930A1 (fr) 1987-11-11
IT8648203A0 (it) 1986-06-30
FR2601248A1 (fr) 1988-01-15
EP0251298A3 (en) 1988-10-26

Similar Documents

Publication Publication Date Title
Svennerholm Gangliosides--a new therapeutic agent against stroke and Alzheimer's disease
Rodden et al. Gangliosides: the relevance of current research to neurosurgery
US4707469A (en) Gangliosides mixture, useful as a therapeutical tool for eliminating painful effects or peripheral neuropathies
CA1314219C (en) Use of exogenous gangliosides in tumoral diseases as a protective factor against toxicity by antitumoral drugs
Kofman et al. Restoration of brain myo-inositol levels in rats increases latency to lithium-pilocarpine seizures
CN100515416C (zh) 能作为抗白血病药物的草药分子
US4910224A (en) Method of modifying the lipid structure and function of cell membranes and pharmaceutical compositions for use therein
Thuy et al. Pharmacological activities and safety of Ganoderma lucidum spores: a systematic review
EP0026223A1 (en) Process and composition for treating disorders by administering lecithin
Kofman et al. Myo-Inositol Attenuates Two Specific Behavioral Effects of
US12440461B2 (en) Methods for treating mitochondrial disorders
US5183807A (en) Use of monosialoganglioside gm, to prevent the development of tolerance to the analgesic effect of morphine and related drugs
KR20110125642A (ko) 당뇨 및 비만을 치료하기 위한 프테로신 화합물의 용도
佐々木琢磨 et al. Antitumor activity and immunomodulatory effect of glycoprotein fraction from scallop Patinopecten yessoensis.
EP0770389A1 (en) Use of monosialoganglioside GM1 or N-dichloro-acetyl-lyso-GM1 for preventing or reversing neuronal degeneration induced by a long term treatment with L-DOPA in the therapy of Parkinson's disease
EP0001924B1 (en) Pharmaceutical composition for administering choline
WO1993011777A1 (en) Amphotericin b composition with enhanced antifungal activity
KR20010040413A (ko) 스피카마이신 또는 이것의 유도체를 사용하여 동통을감소시키거나 예방하는 방법
US20030143282A1 (en) Adenosine A3 receptor agonist
AT392002B (de) Verwendung von peroxydiphosphaten zur herstellung von pharmazeutischen tabletten bzw. pharmazeutischen waesserigen loesungen
AU611393B2 (en) Pharmaceutical compositions for the treatment of cancers
WO2001055083A1 (en) Inositol derivatives and their pharmaceutical use
Miyamoto et al. Host-mediated anticancer activities of tannins
Kofman et al. Myo-Inositol Attenuates Two Specific Behavioral Effects of
WO2013007383A1 (en) Use of lipoteichoic acid in the treatment of cancer in an inflammatory state

Legal Events

Date Code Title Description
MKLA Lapsed